106 related articles for article (PubMed ID: 9013275)
21. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
22. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
Halm U
J Clin Oncol; 2006 Dec; 24(35):5610; author reply 5611. PubMed ID: 17158548
[No Abstract] [Full Text] [Related]
23. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
24. CA 19-9 concentration in peripheral and portal blood of patients operated on for pancreatic tumor.
Szwedziak K; Strzelczyk J
Pol Przegl Chir; 2013 Jan; 85(1):20-8. PubMed ID: 23509198
[TBL] [Abstract][Full Text] [Related]
25. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
Louhimo J; Alfthan H; Stenman UH; Haglund C
Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
[TBL] [Abstract][Full Text] [Related]
26. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
27. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
Lundin J; Roberts PJ; Kuusela P; Haglund C
Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
[TBL] [Abstract][Full Text] [Related]
29. The clinical significance of elevated levels of serum CA 19-9.
Pavai S; Yap SF
Med J Malaysia; 2003 Dec; 58(5):667-72. PubMed ID: 15190651
[TBL] [Abstract][Full Text] [Related]
30. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
31. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
32. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
33. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
35. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
[TBL] [Abstract][Full Text] [Related]
36. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
37. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.
Maithel SK; Maloney S; Winston C; Gönen M; D'Angelica MI; Dematteo RP; Jarnagin WR; Brennan MF; Allen PJ
Ann Surg Oncol; 2008 Dec; 15(12):3512-20. PubMed ID: 18781364
[TBL] [Abstract][Full Text] [Related]
38. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
39. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.
Molina V; Visa L; Conill C; Navarro S; Escudero JM; Auge JM; Filella X; Lopez-Boado MA; Ferrer J; Fernandez-Cruz L; Molina R
Tumour Biol; 2012 Jun; 33(3):799-807. PubMed ID: 22203495
[TBL] [Abstract][Full Text] [Related]
40. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
Santander C; Jiménez I; Martín E; Melón A; Pajares JM
Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]